Member Info for shandypants2

Fidelity are doing the admin the underlying investments are still with L&G. Although this could have prompted a review of holdings and therefore the current sell off

don't be spooked by L&G selling.

I used to work for them and they have strict rules on % of holdings and company size.

When this was <£50m market cap they sold a fair chunk as they could have more than x% in ££ in any micro. So every time the share increased they sold a few.

When this went above £100m different rules would have been applied but these may have been tweaked recently, hence the recent sell off.

Keep the faith

PCGE - what a dog. Agree 100%. Avoid that fraud

he has previously stated that our 49% of immutex is worth a minimum of $100m. That is currently valued at 0 on the balance sheet so assume it's the same with the data. Clearly both the data and the flu vaccine are worth many millions yet the share price has yet to reflect this.

agreed, however, he has consistently stated this, yesterday was not a new comment. I suppose without a clear value and a definitive buyer some feel it won't happen. However, many who have already invested feel it's just a question of time

Mark Ward now at 15% so it appears most of the big buys were his. Does look more promising for IDP with him still accumulating and also now a non exec.
Hopefully £1 plus in the not too distant future

FG appreciate your view but not sure if it's 100% accurate.

ST doesn't even have a retail deal in Australia and hasn't for a few years. The retail revenue increase was predominantly on the back of the Superdrug deal via an ex SD employee who was UK based.
Not sure how Australia can do any UK deals with the 12 hour time difference.

Nuthing was meant to be promoted in store by SD and well positioned on the shelf. I've seen no promotion and bottom shelf positioning (the worst position to have) - what are the Australia team doing about this ??

Finally, based on the last accounts it would appear the customer base is being increased at a loss to IDP - not sure how that's a positive.

i reckon a deal could drop any day now - also possibly a 1pm announcement in line with US partner.

End of Sept date was recently extended but H2 2020 was re-confirmed. Unlikely to be December as on the whole that's a quiet month, so next few weeks IMHO.

A half decent deal will get this above £2 so c 50% upside

https://www.proactiveinvestors.co.uk/companies/news/932284/innovaderma-says-search-for-new-chief-executive-progressing-very-well-932284.html

Edale Capital are proposing a new director.

No one can be overly impressed with Joe Bayer - now holds both Chairman and CEO position after booting out previous CEO who seemed to be doing a good job. When results were announced recently he was invisible. He needs to be promoting this company. How can this company be run out of Australia when over 80% of revenues are UK based?

you are wrong it's a full share takeover only, there has never been a cash alternative. The share price of DVRG is quoted merely for comparison purposes and is a regulatory requirement.
10 MWG for 1 DVRG - that's the only option you have.

Excellent post - also now the UK govt has essentially endorsed OO it will be a lot easier for CF to acquire additional CS contracts (we were in the national news FFS, priceless publicity).
CF estimated potentially 6 additional CS contracts - even 50% of this will be an extra £30m in rev, over £50m if all come in.

Then we have immutex and the data side - neither of which has yet to be monetised but could each we worth c£100m

can see this bouncing after the presentation today. CF is usually quite good in these situations and often drops a few hints re future contracts etc.
UK govt contract is not fully understood too - it's 4 contracts, one paid for with the other 3 reserved slots. So c £40m.
New on Immutex would be good - that could be worth 10p to the share price alone

Great summary BumbleHum but your comment re GBs recent share purchase is incorrect.
When the market crashed in March GB did buy - at c0.83p per skin share - so 8p now in DVRG.
He also contributed in the last fundraise at 1.5p - so now 15p.
He does have loads of shares but none were purchased anywhere near 83p.
Keep up the good work - we need some positivity!!

now into the $11.8k yet share price stubbornly refuses to move up accordingly.

https://www.proactiveinvestors.co.uk/companies/news/931723/-all-pistons-pumping--at-salt-lake-potash-as-project-development-continues-at-pace-931723.html

CEO feeling very confident today in proactive interview. 2 new BOD appointments also a positive IMHO

if an US company do want a full takeover, and potentially that's why ex CEO and founder left as he was against this, then surely it's got be be c£3 per share to get shareholder approval. One company owns c45% of STX and ex CEO c10%. Get these 2 onboard and a deal is pretty much guaranteed

that would be a nice xmas pressie!!!

the patent appeal was European only, the US patent is solid and unchallenged.

Clearly, it's a positive and should improve confidence overall but not sure what, if any, impact it will have re US deal.

I'm fine with the cash position, i think the Q1 2021 date was poorly worded. Since then the 2 planned studies have been delayed and PT20 will now only commence when US deal is concluded.
Cash burn is c £5m a year and STX had over £6m in cash at 30/6.

I'm still pretty confident/hopeful US deal will be announced in next few weeks. Only curveball could be if US company wants to buy STX as a whole. I suspect there was interest last year and previous CEO wouldn't negotiate, hence he has been moved on. If so patent appeal is massive news as there are no obstacles now

Corunna - agree, i remember that quote from earlier in the year, but after mid year results in one of the interviews he also mentioned that the end of Sept date (that was provided in June presentation) may slip a little (or similar - can't remember the exact wording).

So IMHO that means that we must be quite close.

Was expecting share price to slip a little but it has held up quite well. Not sure whether to top at at these prices in anticipation of a 50% increase once deal announced or wait a little in case price slips a little as a few get impatient.

Just playing devils advocate we will be in 2021 in a little over 10 weeks so saying cash until Q1 2021 is not a great buffer. Incidentally, i reckon cash is fine until mid 2021 so not an issue

yes, great appointment.

Not convinced that Joe B knows what he is doing and being based in Oz with a 12 hour difference must make UK communications very difficult.
Hopefully Mark Ward's expertise can help expand the brands globally and maximise our existing customer database - rather than keep growing it at a loss as appears to be the current strategy.
Also hoping Mr Ward can help get us an UK based CEO as Joe doesn't appear to have the contacts